Freudenberg Medical, a CDMO specialising in biopharma, has solidified plans to expand its drug device combination products segment of the business.
The company is investing more than USD $50m in a new Hemoteq AG production facility in Aachen, Germany, one of the most important life science hotspots in Europe.
What will it provide?
The company will triple its manufacturing footprint with the new 130,000 sqft facility in Alsdorf — located near the existing site.
With its ISO Class 7 cleanrooms, laboratories and offices it will serve as a hub for research, development and production; driving innovation in medical coatings.
“The convergence of medical devices and drugs is inspiring a new generation of products that fundamentally improve patients’ outcomes,” says CEO of Freudenberg Medical, Dr Mark Ostwald. “With this innovation driven investment, we are strengthening our position as a strategic partner to our customers, offering vertically integrated solutions along the entire supply chain.”
Promoting sustainability at the new site
The existing industrial building at the site is currently being converted to meet the highest standards from an environmental, energy efficiency and technological standpoint.
A company-owned PV solar power plant will generate the energy needed to operate the site.
Charging stations will enable emission-free commuting, energy recovery from the exhaust air of the clean rooms will be used for heating and an existing heavy oil tank will be converted into a cistern for rainwater utilisation.
